Immunologic basis of cardiac disease after severe COVID-19
重症COVID-19后心脏病的免疫学基础
基本信息
- 批准号:10442251
- 负责人:
- 金额:$ 69.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcuteAdmission activityAwardBiological MarkersBlood specimenCD4 Positive T LymphocytesCOVID-19COVID-19 patientCOVID-19 survivorsCardiacCardiologyCardiomyopathiesCardiopulmonaryCardiovascular systemCellsChronicClinicalCommunicable DiseasesDiffuseEndothelial CellsEnrollmentEpidemicEpidemiologyFibroblastsFibrosisFrequenciesFunctional disorderGoalsHealthHeart AbnormalitiesHeart DiseasesHeart InjuriesHospitalizationImmuneImmune responseImmunofluorescence ImmunologicImmunologicsImmunologyIn VitroInfectionInflammationInflammatoryInfluenzaInjuryInterventionKnowledgeLate EffectsLifeLong COVIDLow PrevalenceLymphopeniaMagnetic ResonanceMeasuresMediatingMicrocirculationMononuclearMuscle CellsMyocardialMyocardial dysfunctionMyocarditisNatural ImmunityOrganParticipantPathologyPatientsPeptidesPericytesPhenotypePost-Acute Sequelae of SARS-CoV-2 InfectionProteinsProtocols documentationRecoveryReportingResearchRespiratory DiseaseRespiratory FailureSARS-CoV-2 infectionScienceSpecialistSpecimenSurvivorsSymptomsT cell responseT-LymphocyteTestingTissuesTroponinViralVirus DiseasesWorkadaptive immune responsebasecardiac magnetic resonance imagingcardiovascular effectscardiovascular injuryclinically relevantcohortcoronary fibrosiscoronavirus diseasecytokinedisabilityexperienceheart damageimmune activationimprovedinfluenza infectioninjured airwaymacrophagemonocytemyocardial injuryneutrophilnovelpandemic diseaseparticlepersistent symptomreceptorresponserisk stratificationsevere COVID-19spatial relationshipstudy populationsystemic inflammatory responsethrombotic complicationswound healing
项目摘要
ABSTRACT
Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) has become a widespread global pandemic. While the predominant clinical manifestation of severe
COVID-19 is respiratory failure, other organ complications such as cardiac injury are common. Cardiac injury
and cardiomyopathy are frequent cardiac manifestations during acute illness. Additionally, some survivors of
COVID-19 are experiencing cardiopulmonary symptoms months after the acute illness, referred to as Post-
Acute Sequelae of SARS-CoV-2 (PASC) or “Long COVID”. Given the frequency of cardiovascular injury during
COVID-19 and the persistence of symptoms for extended periods after the acute illness, there is an urgent
need for studies of the late effects of SARS-CoV-2 on the cardiovascular system. We aim to investigate the
central hypothesis that immune responses to severe COVID-19 cause acute inflammation and injury that result
in clinically relevant myocardial fibrosis and dysfunction over the long-term. Since August 2020, we have been
enrolling patients in a COVID-19 Immune Profiling (IP) Study, which includes a protocol to collect blood
specimens from patients with COVID-19 at admission, during hospitalization, 1-3 months, and 3-12 months
after recovery. We will co-enroll participants from this study and perform cardiac magnetic resonance imaging
(CMR) and additional functional cardiopulmonary assessments at 3-12 months and 2-3 years after recovery.
Our specific aims include, Aim 1) Identify innate immune profiles during severe COVID-19 that predict long-
term cardiac damage. We will focus innate immunity measures in blood specimens collected at admission and
early recovery, Aim 2) Establish whether adaptive immune responses contribute to cardiac injury after COVID-
19. We will quantify responses targeting SARS-CoV-2 as well as explore maladaptive responses targeting
cardiac proteins. Analysis of blood specimens will be supplemented with exploratory studies of cardiac tissue,
and Aim 3) Determine the long-term structural and functional cardiac abnormalities after severe COVID-19.
This includes characterization of cardiac fibrosis and dysfunction, cardiopulmonary dysfunction, and clinical
symptoms. Comparisons will be made with control participants who had influenza infection 1-2 years prior. Our
proposal responds to urgent need for science characterizing long-term cardiac complications following COVID-
19. Our collaborative team has extensive experience spanning cardiology, infectious disease, immunology,
and epidemiology, and will be led by a cardiologist with expertise in CMR and inflammatory cardiomyopathies,
and an infectious diseases specialist with expertise in cardiovascular complications in the context of chronic
viral infections. Successful completion of our work will help understand the long-term cardiovascular effects of
severe COVID-19 illness. This knowledge could, in turn, help enhance health, lengthen life, and reduce illness
and disability in COVID-19 survivors.
摘要
2019年冠状病毒病(COVID-19)由严重急性呼吸道综合征冠状病毒2(SARS-
CoV-2)已成为一种广泛的全球流行病。虽然重症肌无力的主要临床表现
COVID-19是呼吸衰竭,其他器官并发症如心脏损伤是常见的。心脏损伤
和心肌病是急性疾病期间常见的心脏表现。此外,一些幸存者
COVID-19在急性疾病后几个月出现心肺症状,称为后
SARS-CoV-2急性后遗症(PASC)或“长期COVID”。考虑到心脏血管损伤的频率
COVID-19和急性疾病后长时间持续存在的症状,
需要研究SARS-CoV-2对心血管系统的晚期影响。我们的目标是调查
中心假设是,对严重COVID-19的免疫反应会导致急性炎症和损伤,从而导致
临床相关的心肌纤维化和功能障碍的长期。自2020年8月以来,我们一直
招募患者参加COVID-19免疫分析(IP)研究,其中包括采集血液的方案
COVID-19患者入院时、住院期间、1-3个月和3-12个月的标本
恢复后。我们将共同招募本研究的参与者,并进行心脏磁共振成像
(CMR)并在恢复后3-12个月和2-3年进行额外的功能性心肺评估。
我们的具体目标包括,目标1)确定严重COVID-19期间的先天免疫特征,预测长期-
心脏损伤我们将重点关注在入院时采集的血液样本中的先天免疫措施,
早期恢复,目的2)确定适应性免疫应答是否有助于COVID后的心脏损伤-
19.我们将量化针对SARS-CoV-2的反应,并探索针对SARS-CoV-2的适应不良反应。
心肌蛋白血液样本的分析将补充心脏组织的探索性研究,
和目的3)确定严重COVID-19后的长期心脏结构和功能异常。
这包括心脏纤维化和功能障碍、心肺功能障碍和临床
症状将与1-2年前感染流感的对照受试者进行比较。我们
提案回应了对COVID-19后长期心脏并发症的科学表征的迫切需求-
19.我们的合作团队拥有丰富的经验,涵盖心脏病学,传染病,免疫学,
和流行病学,并将由一位在CMR和炎症性心肌病方面具有专长的心脏病专家领导,
和一名传染病专家,在慢性病背景下具有心血管并发症方面的专业知识,
病毒感染我们的工作的成功完成将有助于了解长期心血管影响的
严重的COVID-19疾病。这些知识反过来可以帮助增进健康、延长寿命和减少疾病
和残疾。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason V Baker其他文献
Jason V Baker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason V Baker', 18)}}的其他基金
Immunologic basis of cardiac disease after severe COVID-19
重症COVID-19后心脏病的免疫学基础
- 批准号:
10650182 - 财政年份:2022
- 资助金额:
$ 69.46万 - 项目类别:
Optimization of a behavioral intervention to increase physical activity in older adults living with HIV
优化行为干预以增加艾滋病毒感染者老年人的体力活动
- 批准号:
10693938 - 财政年份:2022
- 资助金额:
$ 69.46万 - 项目类别:
Optimization of a behavioral intervention to increase physical activity in older adults living with HIV
优化行为干预以增加艾滋病毒感染者老年人的体力活动
- 批准号:
10481551 - 财政年份:2022
- 资助金额:
$ 69.46万 - 项目类别:
Clinical and immunologic factors underlying heart failure with preserved ejection fraction among persons with HIV in South Africa
南非艾滋病毒感染者射血分数保留的心力衰竭的临床和免疫因素
- 批准号:
10685376 - 财政年份:2021
- 资助金额:
$ 69.46万 - 项目类别:
Clinical and immunologic factors underlying heart failure with preserved ejection fraction among persons with HIV in South Africa
南非艾滋病毒感染者射血分数保留的心力衰竭的临床和免疫因素
- 批准号:
10325041 - 财政年份:2021
- 资助金额:
$ 69.46万 - 项目类别:
PrEP iT! A Pilot Test of a Mobile Peer Support Intervention to Optimize PrEP Adherence and Retention in PrEP Care
PrEP iT!
- 批准号:
10116478 - 财政年份:2019
- 资助金额:
$ 69.46万 - 项目类别:
Treatment to reduce inflammation and improve immune recovery among older HIV pts
减少老年艾滋病患者炎症并改善免疫恢复的治疗
- 批准号:
8641495 - 财政年份:2014
- 资助金额:
$ 69.46万 - 项目类别:
Treatment to reduce inflammation and improve immune recovery among older HIV pts
减少老年艾滋病患者炎症并改善免疫恢复的治疗
- 批准号:
9038208 - 财政年份:2014
- 资助金额:
$ 69.46万 - 项目类别:
Treatment to reduce inflammation and improve immune recovery among older HIV pts
减少老年艾滋病患者炎症并改善免疫恢复的治疗
- 批准号:
8883185 - 财政年份:2014
- 资助金额:
$ 69.46万 - 项目类别:
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease
靶向抗凝治疗可减少治疗艾滋病毒疾病中的炎症
- 批准号:
8846913 - 财政年份:2014
- 资助金额:
$ 69.46万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 69.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 69.46万 - 项目类别:
Operating Grants